{"filing":{"accession_number":"0001104659-26-085073","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"tm2620898d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926085073/tm2620898d1_8k.htm"},"events":[{"id":18803,"run_id":16917,"accession_number":"0001104659-26-085073","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 disclosure reports the results of Transcode Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026. The filing details voting outcomes on seven proposals, including approval of convertible preferred stock issuances (Proposals 1–2), a Standby Equity Purchase Agreement and convertible notes (Proposal 3), election of six directors (Proposal 4), amendment to the 2021 Stock Option and Incentive Plan (Proposal 5), ratification of the independent auditor (Proposal 6), and adjournment authority (Proposal 7). All proposals were approved. The disclosure is material because shareholder approval of dilutive equity issuances and director elections directly affects investor interests and capital structure.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17723,"accession_number":"0001104659-26-085073","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of Transcode Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026. The filing details voting outcomes on seven proposals, including approval of convertible preferred stock issuances (Proposals 1–2), a Standby Equity Purchase Agreement and convertible notes (Proposal 3), election of six directors (Proposal 4), amendment to the 2021 Stock Option and Incentive Plan (Proposal 5), ratification of the independent auditor (Proposal 6), and adjournment authority (Proposal 7). All proposals were approved. The disclosure is material because shareholder approval of dilutive equity issuances and director elections directly affects investor interests and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:16:42.077079+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17723,"accession_number":"0001104659-26-085073","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of Transcode Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026. The filing details voting outcomes on seven proposals, including approval of convertible preferred stock issuances (Proposals 1–2), a Standby Equity Purchase Agreement and convertible notes (Proposal 3), election of six directors (Proposal 4), amendment to the 2021 Stock Option and Incentive Plan (Proposal 5), ratification of the independent auditor (Proposal 6), and adjournment authority (Proposal 7). All proposals were approved. The disclosure is material because shareholder approval of dilutive equity issuances and director elections directly affects investor interests and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:16:42.077079+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-20"}]}